ArticleScientific reports2025
Global, regional, and national burden of nonrheumatic calcific aortic valve disease based on GBD study 2021.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Review of Sex Differences in Patients with Aortic Stenosis: A Focus on Diagnostic and Treatment Differences, a Narrative Review.Journal of clinical medicine · 2026Review
- Aortic valve stenosis serum IGFBP2 mediates female-specific Evogliptin resistance in valve myofibroblasts.Cell reports · 2026Article
- Comparisons of the Burden and Quality of Care of Nonrheumatic Valvular Heart Disease in Asia and Globally.Journal of the American Heart Association · 2026Article
- Add-Ons of Heart Disease from the Cardiosurgical Perspective: Gender, Blood Groups and Renal Function.Medical sciences (Basel, Switzerland) · 2026Article
- Review
- Integrated biomarker landscape for the early detection and management of calcific aortic valve disease.European journal of clinical investigation · 2026Review
- The correlation between the atherogenic index of plasma and aortic valve calcification in the general population: a retrospective observational cohort study.Frontiers in endocrinology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Calcific aortic valve disease (CAVD) is among the most prevalent forms of nonrheumatic valvular heart disease, imposing a substantial global health burden. This study examined CAVD trends to provide insights for the development of effective prevention strategies. Using Global Burden of Disease Study 2021 (GBD 2021) data, we analyzed the age-standardized prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of CAVD, along with trends, age- and sex-specific patterns, contributing factors, and projections through 2036. From 1992 to 2021, the number of global CAVD cases rose from 4.97 to 13.32 million and the age-standardized prevalence rate (ASPR) increased from 130.82 to 158.35 per 100,000 people. While both the ASPR and age-standardized incidence rate (ASIR) steadily increased, the age-standardized mortality rate (ASMR) and age-standardized DALYs rate (ASDR) declined. The burden of CAVD progressively worsened with age. Males generally had higher prevalence and incidence rates compared with females. However, in individuals > 85 years, females exhibited significantly higher mortality and DALY burdens. The CAVD burden was positively correlated with the sociodemographic index (SDI); the correlation was stronger in High SDI regions compared with Low SDI regions, and this gap widened over the last three decades. Population growth and aging were the primary contributors to the increasing burden, while epidemiological transitions helped reduce the ASMR and ASDR in regions with a high SDI. By 2036, the ASPR, ASIR, ASMR, and ASDR of CAVD are projected to decline in the High and High-middle SDI regions. In contrast, the ASPR and ASIR are expected to continue to increase, whereas the ASMR and ASDR are anticipated to remain relatively stable in other SDI regions. Although significant progress has been made globally in the prevention and treatment of CAVD, the complex demographic and regional disparities underscore the need for targeted prevention and treatment strategies to further alleviate the burden and enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.